EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Shortened Obinutuzumab Infusion Is Safe and Reduces Chair Time in Frontline Treatment of Chronic Lymphocytic Leukemia: A Real‐World Study

Dominika Écsiová iD, Eva Vejražková iD, Pavel Vodárek iD, Petra Rozsívalová iD, Lukáš Smolej iD, Pavel Žák iD, Martin Šimkovič iD

Cancer Medicine · 2026-11 · 15 (11)

DOI: 10.1002/cam4.72409 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 01.11.2026. Verfasst von Dominika Écsiová und 6 weiteren Autor:innen. Beteiligte Einrichtung: 4th Department of Internal Medicine - Hematology, University Hospital Hradec Králové, Hradec Králové, Czech Republic. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Univerzita Karlova v Praze, Ministerstvo Zdravotnictví Ceské Republiky.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Obinutuzumab‐based regimens are established frontline treatments for chronic lymphocytic leukemia (CLL), but infusion‐related reactions (IRRs) and prolonged administration increase patient burden and outpatient chair occupancy. Evidence on shortened obinutuzumab infusion in CLL remains limited.

Aims

To evaluate the safety, feasibility, and clinical outcomes of a 2‐h obinutuzumab infusion protocol in treatment‐naïve CLL.

Methods

This retrospective single‐center cohort study included 112 treatment‐naïve patients receiving venetoclax–obinutuzumab ( n = 72) or obinutuzumab–chlorambucil ( n = 40). From cycle 1 day 8 onward, patients were managed according to either a shortened‐infusion strategy (Short; n = 64) or a standard‐duration strategy (Long; n = 48). The primary outcome was IRR incidence and severity; secondary outcomes included chair time, response rate, and progression‐free survival.

Results

IRR rates did not differ significantly between the Short and Long groups (71.9% vs. 83.3%; odds ratio, 0.51; 95% confidence interval, 0.17–1.41; p = 0.18). Most IRRs occurred during the first infusion (87.4%), before implementation of the shortened protocol. Because cycle 1 day 1 and day 2 were administered using the same standard protocol in both groups, the safety comparison relevant to the shortened‐infusion strategy begins at cycle 1 day 8; IRRs were infrequent from cycle 1 day 8 onward, and none occurred from cycle 1 day 15 onward, when eligible patients in the Short group were receiving the 2‐h infusion. Grade 2 reactions predominated (91.6%); no Grade 4 IRRs occurred among the 112 patients included in the analysis. The shortened protocol saved 1.8 h per visit and 11.2 h per patient (42%). No apparent adverse signal in response or progression‐free survival was observed.

Conclusions

In frontline CLL care, a 2‐h obinutuzumab infusion from cycle 1 day 8 was feasible, safe, and substantially reduced chair time, supporting its use to improve outpatient treatment efficiency.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Lymphocytic, Chronic, B-CellAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsHumansRetrospective StudiesFemaleAgedMaleInfusions, IntravenousMiddle AgedAged, 80 and overDrug Administration ScheduleChlorambucil

Stichwörter der Autor:innen

chronic lymphocytic leukemiainfusion‐related reactionsobinutuzumabshortened infusion

Substanzen

obinutuzumabAntibodies, Monoclonal, HumanizedChlorambucil

Autor:innen und Institutionen

  • 4th Department of Internal Medicine - Hematology, University Hospital Hradec Králové, Hradec Králové, Czech Republic.
  • Faculty of Medicine in Hradec Králové, Charles University, Hradec Králové, Czech Republic.
  • Tissue Bank, University Hospital Hradec Králové, Hradec Králové, Czech Republic.
  • Department of Clinical Pharmacy, Hospital Pharmacy, University Hospital Hradec Králové, Hradec Králové, Czech Republic.

ORCID-Profile: Dominika Écsiová, Eva Vejražková, Pavel Vodárek, Petra Rozsívalová, Lukáš Smolej, Pavel Žák, Martin Šimkovič

Förderung

  • Univerzita Karlova v Praze
  • Ministerstvo Zdravotnictví Ceské Republiky

Zitieren

APA

Écsiová, D., Vejražková, E., Vodárek, P., Rozsívalová, P., Smolej, L., Žák, P., & Šimkovič, M. (2026). Shortened Obinutuzumab Infusion Is Safe and Reduces Chair Time in Frontline Treatment of Chronic Lymphocytic Leukemia: A Real‐World Study. Cancer Medicine, 15(11). https://doi.org/10.1002/cam4.72409

Vancouver

Écsiová D, Vejražková E, Vodárek P, Rozsívalová P, Smolej L, Žák P, et al. Shortened Obinutuzumab Infusion Is Safe and Reduces Chair Time in Frontline Treatment of Chronic Lymphocytic Leukemia: A Real‐World Study. Cancer Medicine. 2026;15(11). doi:10.1002/cam4.72409

BibTeX
@article{csiov2026,
  author = {Écsiová, Dominika and Vejražková, Eva and Vodárek, Pavel and Rozsívalová, Petra and Smolej, Lukáš and Žák, Pavel and Šimkovič, Martin},
  title = {Shortened Obinutuzumab Infusion Is Safe and Reduces Chair Time in Frontline Treatment of Chronic Lymphocytic Leukemia: A Real‐World Study},
  journal = {Cancer Medicine},
  year = {2026},
  volume = {15},
  number = {11},
  doi = {10.1002/cam4.72409}
}
Kostenlos starten →